基于影像组学的超声模型鉴别子宫肉瘤与肌瘤:ROMUS 回顾性多中心预试验
本研究为回顾性多中心预试验,纳入 200 例患者(100 例子宫肉瘤,100 例普通型肌瘤),提取超声影像组学特征构建机器学习模型。验证集中,整合患者年龄与 8 个影像组学特征的 XGBoost 模型鉴别肉瘤与肌瘤的 AUC 为 0.93,敏感度 0.93,特异度 0.83。
要点
- 整合年龄与 8 个影像组学特征的 XGBoost 模型在验证集 AUC 达 0.93。
- 该模型敏感度 0.93、特异度 0.83,敏感度高于原超声医师主观评估。
- 模型性能与原超声医师主观评估相似,但特异度较低。
核心结论
- 包含 8 个影像组学特征和患者年龄的模型对鉴别子宫肉瘤与肌瘤具有较好的区分和分类性能。
- 其分类能力与原超声检查者主观评估相似,敏感度更高但特异度较低。
研究设计与样本
- 回顾性、多中心、预试验病例对照研究,纳入 200 例患者(100 例子宫肉瘤,100 例普通型肌瘤),于 2010 年 1 月至 2022 年 6 月接受术前超声检查。
- 队列按 70:30 分为训练集和验证集,各亚组中肌瘤与肉瘤比例相同。
主要发现
- 验证集中,整合患者年龄与影像组学特征的 XGBoost 模型表现最佳,AUC 0.93,敏感度 0.93,特异度 0.83(恶性风险截断值 47%)。
- 仅整合影像组学特征的模型验证集 AUC 0.87,敏感度 0.87,特异度 0.83。
- 验证集中,原超声检查者主观评估敏感度 0.87,特异度 1。
- 两名独立专家回顾灰度超声图像(盲于临床病史)的敏感度 0.87,特异度 0.80(两名评估者结果相同)。
关键数值与推荐
- 恶性风险截断值 47% 为训练集中基于约登指数获得最高正确分类数的截断值。
- XGBoost 模型验证集 AUC 0.93,敏感度 0.93,特异度 0.83。
- 仅影像组学特征模型验证集 AUC 0.87,敏感度 0.87,特异度 0.83。
- 原超声检查者主观评估验证集敏感度 0.87,特异度 1。
- 专家回顾灰度图像验证集敏感度 0.87,特异度 0.80。
临床怎么用
- 若影像组学模型性能得到证实,将自动影像组学分析整合至超声机器软件可能帮助超声检查者鉴别肉瘤与良性肌瘤。
局限性
- 本研究为回顾性预试验,需大规模前瞻性研究纳入良性肌瘤变异型以确认影像组学鉴别肉瘤与肌瘤的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop machine-learning models that incorporate clinical information and radiomics features extracted from ultrasound images to distinguish uterine sarcomas from leiomyomas. METHODS: This retrospective, multicenter, pilot case-control study included 200 patients (100 with a uterine sarcoma and 100 with a usual-type leiomyoma, i.e. including no benign leiomyoma variants) who underwent preoperative ultrasound examination between January 2010 and June 2022. The patient cohort was split (70:30) into training and validation sets, with the same proportion of leiomyomas and sarcomas in each subset. We extracted radiomics features belonging to different families: intensity-based statistical features and textural features. The variables used in model building were patient age and the radiomics features that differed statistically significantly between sarcomas and leiomyomas and that were not redundant based on Spearman's correlation coefficient. Logistic regression, random forest, extreme gradient boosting (XGBoost) and support vector machine models were tested in the model development process. We evaluated the performance of the models in differentiating between sarcomas and leiomyomas using the area under the receiver-operating-characteristics curve (AUC), accuracy, sensitivity and specificity. We compared these results to those of subjective assessment by the original ultrasound examiner and to those of two independent expert ultrasound examiners who, blinded to clinical history, reviewed the same grayscale ultrasound images as those used for the radiomics analysis. RESULTS: Sixty-three radiomics features were extracted. Of these, eight differed statistically significantly between sarcomas and leiomyomas and were not correlated, so were selected for inclusion in model building. In the validation set, the model that performed best in differentiating between sarcomas and leiomyomas was an XGBoost model integrating patient age and radiomics features. In the validation set, this model had an AUC of 0.93, sensitivity of 0.93 and specificity of 0.83, at a risk-of-malignancy cut-off of 47% (the cut-off that yielded the highest number of correct classifications based on Youden's index in the training set). The corresponding results for the model integrating only the radiomics features were: AUC of 0.87, sensitivity of 0.87 and specificity of 0.83. Subjective assessment by the original ultrasound examiner had a sensitivity of 0.87 and specificity of 1 in the validation set, while retrospective review of grayscale ultrasound images by ultrasound experts had a sensitivity of 0.87 and specificity of 0.80 (same results for both reviewers). CONCLUSION: A model including eight radiomics features and patient age demonstrated reasonably good discriminative and classification performance for distinguishing uterine sarcomas from leiomyomas. Its classification ability was similar to that of subjective assessment by the original ultrasound examiner, being more sensitive but less specific. To confirm the role of radiomics for discriminating between uterine sarcomas and leiomyomas, large prospective studies including benign leiomyoma variants are needed. If good performance of radiomics models can be confirmed, integrating automated radiomics analysis into ultrasound machine software may help ultrasound examiners to discriminate between sarcomas and benign leiomyomas. © 2026 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Ciccarone F, Rizzi A, Biscione A, et al. Radiomics-based ultrasOund Model for differentiating Uterine Sarcomas from leiomyomas (ROMUS): a retrospective pilot Multicenter Italian Trials in Ovarian Cancer (MITO) study. Ultrasound Obstet Gynecol. 2026. PMID: 41791853. doi:10.1002/uog.70187
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。